Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well AMBS is renting from Johnson & Johnson
Johnson & Johnson is an American multinational medical devices, pharmaceutical and consumer packaged goods manufacturer founded in 1886
http://www.jnj.com/
My Guess is Eli Lilly and Company is an American global pharmaceutical company with headquarters located in Indianapolis, Indiana, in the United States. The company also has offices in Puerto Rico and 17 other countries.
But then there is Europe, Roche? Well lets think someone might want the whole world market. Who would that be?
Next week world show of Lympro should hit news wires.
I'm just "In my Humble Opinion" IMHO that this will
EXPLODE.
Come on this stock really should have 200mm market cap;
200 million or so right now is about three times higher,
or lets say .30 cents a share really guys are trading this
for pennies, when it can go to dollars.
Perfect Post Risk at Perfect time. Becton, Dickinson and Company is an American medical technology company that manufactures and sells medical devices, instrument systems and reagents.
http://www.bd.com/us/
"On LymPro: Following the announcement of positive analytical performance on LymPro last October, Amarantus is pushing forward with a 7-year follow-up analysis of the 88 patients studied in the Phase 1 trial. This will be an incredibly important longitudinal analysis for the validation of LymPro and help management secure a development and commercialization partnership once completed. The next step is to establish long-term analytical performance to support commercial launch in 2015 (note: management guidance is "second half of 2014")."
End Quote from below reference:
http://seekingalpha.com/article/2027661-new-cash-to-help-drive-amarantus-pipeline
Partnership is next - Hold on to the Rocket Ship
Now O'l bloody Chap that Beetter! English accent'.
Now lets get the ball rolling shall we.
Lilly to Showcase Data from its Alzheimer's Disease Portfolio at the Alzheimer's Association International Conference 2014 (AAIC 2014)
http://finance.yahoo.com/news/lilly-showcase-data-alzheimers-disease-120000436.html
Yes agreed, but in all fairness the UK has some news, we do too.
Just want to keep the scales balanced across the pond.
quote: "LONDON—Shares in British biotech group Proteome Sciences PRM.LN +16.67% PLC jumped more than 15% Tuesday after the company made what it called a "significant step" toward developing a blood test for Alzheimer's disease.
In a study co-written with researchers from King's College London, the company said it has identified a set of 10 proteins in the blood which can predict the onset of Alzheimer's, the most common form of dementia." End Quote: Reference
http://online.wsj.com/articles/alzheimers-blood-test-progress-boosts-british-biotech-company-1404823119?tesla=y&mg=reno64-wsj&url=http://online.wsj.com/article/SB10001424052702304418604580016780950559108.html
Sent UK Telegraph response to Blood Test
They need to know
Poster Presentation Details
Date: July 14 2014
Location: Exhibit Hall (Bella Center Convention Center)
Poster Session Time: 11:45a.m. - 2:15 p.m.
Session Type: AAIC Poster Presentation
Proposal Number: 45402
Presentation Title: Employing Lymphocyte Proliferation as a means to Asses Cell Cycle Dys-regulation in Cognitively Impaired Subjects: Clinical Performance of the LymPro Assay
Poster Number: P2-389
Date: July 15, 2014
Location: Exhibit Hall (Bella Center Convention Center)
Poster Session Time: 11:45 a.m. – 2:15 p.m.
Session Type: AAIC Poster Presentation
Proposal Number: 45240
Presentation Title: Retrospective Analysis of Clinical Prognosis of Subjects from a 2008 study using the LymPro assay
Poster Number: P3-118
Date: July 15, 2014
Location: Exhibit Hall (Bella Center Convention Center)
Poster Session Time: 11:45 a.m. – 2:15p.m.
Session Type: AAIC :Poster Presentation
Proposal Number: 45398
Presentation Title: Employing Lymphocyte Proliferation as a means to Asses Cell Cycle Dys-regulation in Cognitively Impaired Subjects: Analytical Performance of the LymPro Assay
Poster Number: P3-117
Yes great time to buy
Bought 100.000 every two weeks
AAIC schedule for Amarantus Lympro located:
In the Lower search field, not the upper search field.
Type Lympro in the lower search area not the Upper.
http://preview.alz.org/aaic/planner/lite.asp?_ga=1.79880017.751975466.1404570031
Thanks Solantey
LymPro Test ®
The Lymphocyte Proliferation Test (“LymPro Test ®”, or “LymPro”) is a diagnostic blood test for Alzheimer’s disease originally developed by the University of Leipzig in Germany. The test works by evaluating the cell surface marker CD69 on peripheral blood lymphocytes following a mitogenic stimulation. The underlying scientific basis for LymPro is that Alzheimer’s patients have a dysfunctional cellular machinery that inappropriately allows mature neurons in the brain to enter the mitotic process (cell division /cell cycle). When this happens the neurons start the cell division process, but cannot complete that process. As a result, a number of cytokines and other genes are upregulated, ultimately leading to cell death by apoptosis. This inappropriate cell division activation process is also present in the lymphocytes of Alzheimer’s patients, as lymphocytes share a similar cellular division machinery with brain neurons. We measure the integrity of this cellular division machinery process by measuring CD69 upregulation in response to the mitogenic stimulation. If CD 69 is upregulated it means that the cellular division machinery process is correct and Alzheimer’s is not present. If CD69 is not upregulated, it means there is a dysfunctional cellular division machinery process, and Alzheimer’s is more likely. To date, data has been published in peer-reviewed publications on LymPro with 160 patients, demonstrating 92% co-positivity and 91% co-negativity with an overall 95% accuracy rating for LymPro.
Eltoprazine
Eltoprazine is a small molecule drug candidate that is a selective partial agonist on the 5HT1-A and 5HT1-B receptors of the serotonergic system in the brain originally discovered and developed by Solvay Pharmaceuticals (now Abbvie). The serotonergic system has been associated with a wide range of disorders motor and behavioral disorders including aggression, cognition, attention and control. The Company is developing Eltoprazine for the treatment of the primary side effect of current Parkinson’s disease medication Levadopa-Induced Dyskinesia (“PD LID”), as well as Adult Attention Deficit Hyperactivity Disorder (“Adult ADHD”). To date, over 700 patients have been dosed with Eltoprazine at varying doses as high as 30mg; the active dose in both PD LID and Adult ADHD is 5mg. Primary and secondary endpoints have been met for Eltoprazine in Phase 2 trials in PD LID and Adult ADHD.
MANF
Mesencephalic Astrocyte-derived Neurotrophic Factor (“MANF”) is an endogenous, evolutionally conserved and widely expressed protein that was discovered by the Company’s Chief Scientific Officer Dr. John Commissiong. MANF acts on a variety of molecular functions, including as a part of the endoplasmic reticulum stress response (“ER-SR”) system of the unfolded protein response (“UPR”). MANF has demonstrated efficacy as a disease-modifying treatment in various animal models, including Parkinson’s disease, retinitis pigmentosa, cardiac ischemia and stroke. The Company has made a strategic decision to focus the development of MANF in orphan indications and is currently evaluating the most appropriate indication for development based on data currently being assembled internally, by contract research organizations and academic collaborators.
68-Tele you did not answer any question you simple post same junk over and over on web site.
Don't waste my time.
Amarantus' Presentations - AAIC Meeting, July 12-17, 2014 in Copenhagen, Denmark
Employing Lymphocyte Proliferation as a means to Asses Cell Cycle Dys-regulation in Cognitively Impaired Subjects: Clinical Performance of the LymPro Assay
P2-389
11:45am - 2:15pm
Mon, Jul 14
Employing Lymphocyte Proliferation as a means to Asses Cell Cycle Dys-regulation in Cognitively Impaired Subjects: Analytical Performance of the LymPro Assay
P3-117
11:45am - 2:15pm
Tue, Jul 15
Retrospective Analysis of Clinical Prognosis of Subjects from a 2005 study using the LymPro assay
P3-118
11:45am - 2:15pm
Tue, Jul 15
Great time to announce a "big pharma" marketing partnership for LymPro. Roche in the E.U. and Quest Diagnostics in the U.S. would make great partners.
Stay tuned for news.
Note: Jason Napadano tweeted that his next article on Amarantus would be after the AAIC meeting.
Twitter: @AmarantusBio .... 9,955 followers.
p.s. Expecting the share price to move substantially higher from here through the up-listing in 4Q2014. Major milestones ahead.
Great advance information Solantey on AAIC Conference
Hopefully the "NONE" helpful posts will be removed.
Solantey, do you have a reference link to this information:
Amarantus' Presentations - AAIC Meeting, July 12-17, 2014 in Copenhagen, Denmark
Employing Lymphocyte Proliferation as a means to Asses Cell Cycle Dys-regulation in Cognitively Impaired Subjects: Clinical Performance of the LymPro Assay
P2-389
11:45am - 2:15pm
Mon, Jul 14
Employing Lymphocyte Proliferation as a means to Asses Cell Cycle Dys-regulation in Cognitively Impaired Subjects: Analytical Performance of the LymPro Assay
P3-117
11:45am - 2:15pm
Tue, Jul 15
Retrospective Analysis of Clinical Prognosis of Subjects from a 2005 study using the LymPro assay
P3-118
11:45am - 2:15pm
Tue, Jul 15
Great time to announce a "big pharma" marketing partnership for LymPro. Roche in the E.U. and Quest Diagnostics in the U.S. would make great partners.
Stay tuned for news.
Note: Jason Napadano tweeted that his next article on Amarantus would be after the AAIC meeting.
Twitter: @AmarantusBio .... 9,955 followers.
p.s. Expecting the share price to move substantially higher from here through the up-listing in 4Q2014. Major milestones ahead.
AAIC Meeting, July 12-17, 2014 in Copenhagen, Denmark
where is Amarantus in all of this another spectator
or a Show in of itself.
Do some research, on the AAIC site find me one reference to
Lympro
ONE
AAIC Meeting, July 12-17, 2014 in Copenhagen, Denmark
http://www.alz.org/aaic/overview.asp
What is Amarantus doing at this Conference?
Attending Don't see any Lymphocyte Proliferation test (“LymPro Test®”) for Alzheimer’s disease mentioned in any of the
www.alz.org/aaic
web sit at all. Just thinking there shoujld be something in the very recent past. Anything any One?
Its nice the CEO can go and show boat at these world class conferences, but where is the Lympro - MEAT here.
Money Train leaving station AMBS Get yours next week
Too bad some of you sold I bought a bunch this week.
About Amarantus
Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. The Company has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready indication for Parkinson's Levodopa induced dyskinesia and Adult ADHD. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test(r)") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). For further information please visit www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.
Why the selling on recent good news?
Well all that toxic financing our leader did last couple of years,
still is not flushed out, I don't care what Ptronic says,
the lPC affiliates don't have enough cash to cover all the
bad deals that GC did in the past two years.
He's luck this is not sub penny based on his actions.
Approval Times for Drugs
ORPHAN Drugs - Time line
Standard approval times for branded drugs are six to 10 months.
Under the Prescription Drug User Fee Act, drugs are reviewed by:
• Standard Review, which is applied to a drug that offers at most, only minor improvement over existing marketed therapies. The goal is that a Standard Review of a new drug application be accomplished within a ten-month time frame.
• Priority Review, which is given to drugs that offer major advances in treatment, or provide a treatment where no adequate therapy exists. The goal is to complete a Priority Review is six months. Priority Review status applies to drugs that are used to treat serious diseases and drugs for less serious illnesses.
Generic drug applications are reviewed in a "first in, first out" order, with the exception of a few types of applications, such as first-time generics and AIDS drugs under PEPFAR. There are not set goals for review times.
Currently generic drug applications are taking about 20 months to review due to a backlog of a high volume of applications.
http://pharmacy.about.com/od/TheDrugIndustry/a/The-Fda-Drug-Approval-Process.htm
Would Theranos be the Beat All Blood Test
Theranos, nano blood samples at fraction of normal costs.
http://www.theranos.com/
Its nice to know Big Pharma is in discussions,
but really Fumi do we need your almost disclosure and lose your job over this? I"m happy to wait for the public release of information.
All aboard, the Money Train is Leaving the Station.
AMBS and MANF - MANF, Wolfram, and Diabetes #6: Protecting remaining tissues
Yesterday, I articulated our strategy for protecting remaining beta cells and brain cells with MANF. 1. Inject recombinant MANF to patients. 2. Stabilize endogenous MANF 3. Activate a receptor for MANF I feel that these are realistic plans. The same strateg...?
https://plus.google.com/103555663941320852454/posts/KfCATiMA3Xg
JPetronic? >> Can AMBS work with Theranos. Theranos is introducing CLIA-certified laboratory services with the ability to run its tests on micro-samples.
Theranos™ Wellness Centers
Quote:
"We’re bringing lab testing closer to you. In the coming months, our Theranos Wellness Centers will bring our new experience to convenient, neighborhood locations."
New Theranos Wellness Centers at Wallgreens
http://www.theranos.com/for-providers
Micro blood samples faster than Qwest Diagnostics.
See the FOR PROVIDERS / TEST MENU
Like I have always said, get rid of the Football player.
You guys follow him like he some god, this company
is a IP company, and its run by a football player mentality.
Get a clue get a new CEO.
How hard is it to sign a Big Pharma with Lympro?
Is GC holding out for more money, while he lines the pockets of all of his connections with our money?
Get a clue you clueless board members
Fattah Advances Global Alzheimer's Framework in FY15 State and Foreign Operations Appropriations Bill
06/24/14
WASHINGTON—The House Appropriations Committee passed language today in a bipartisan vote that would support a framework for a global Alzheimer’s fund to combat the growing threat of the disease worldwide. Congressman Fattah (D-PA), a Senior Member of the Committee, pushed for the language to be included in the FY 2015 State and Foreign Operations Appropriations bill. Together with Congressman Chris Smith (R-NJ), Fattah introduced related legislation earlier this year that called on the United States to lead an international effort towards treating and curing Alzheimer’s and other dementias.
http://fattah.house.gov/press/fattah-advances-global-alzheimers-framework-in-fy15-state-and-foreign-operations-appropriations-bill/
Time to buy its pre- launch into orbit t minus 45 days and counting
What is a endoplasmic reticulum below,
you can see what is being stressed out in these indications
and what MANF is protecting.
https://www.google.com/search?q=endoplasmic+reticulum&tbm=isch&tbo=u&source=univ&sa=X&ei=ViWoU73AOKehsQSw6IGgBA&sqi=2&ved=0CDMQsAQ&biw=1522&bih=936
On the Sidelines? Better be exposed. Its one thing
to think you can time this thing, its another to be long
when the real news comes out, its going bye, bye.
I know some of you have 5 million , 7million, 3 million,
even 20 million shares of this piece of shit stock AMBS,
but when the Revenue projections come and Joint Venture (JV)
for Lympro - this stock will be up several hundred precent.
Anyway, I'm exposed in a big way and am not worried about a penny or two are you? Really in the big picture of things really
worried about a penny, he fella you got a dime?
I like your partners(image), see attached White Paper Lympro
http://content.stockpr.com/amarantus/files/pdf/AMBS_LymPro_whitepaper_9may2013_2300.pdf
Would not be surprised to see some pull back here.
Would like to be in the OZ movie the Yellow Brick Road,
but some stocks that run for 15 days pull back some.
Before the pending milestones. Also we have a situation
over-seas that could push markets down 1-2% for now.
I'm just saying. AMBS with proper news will move on its own
to new highs, just recently seems pretty rosy to me.
To all the cheer leaders on this board.
You can re-post old news 1 million times.
Until the Football Player makes an agreement
with our IP, nothing is going to happen.
Treatment of motor and movement disorder side effects associated with parkinson's disease treatments
WO 2013188210 A2
http://www.google.com/patents/WO2013188210A2?cl=en
Abstract
This invention provides methods of treating motor disorder side effects associated with the administration of levodopa to a subject having Parkinson's disease, by administering a dose of eltoprazine or a pharmaceutically acceptable acid addition salt thereof. In particular, the invention provides methods for reducing dyskinesia associated with Parkinson's disease treatments, and effective doses of eltoprazine or a pharmaceutically acceptable acid addition salt thereof.
Inventors: Emer Leahy, Bavani Shankar
AMBS - Amarantus BioScience
http://ih.advfn.com/p.php?pid=squote&symbol=AMBS
This company has some very significant progress occurring
right now and some are predicting its over 1 buck this year.
Its .09cents and on the cusp of a Alzheimer's Blood test to commercialize this year for revenue.
Other block buster drugs in pipeline.
I started re-buying in March 2014 have not sold a share,
stock is moved from low six's to almost eleven recently,
with news pending on the Blood Test Joint Venture Partner,
we are getting excited about the near term prospects as well as
long term.
One advisor to the Board of Directors is Dr. Rubinfield one of the founders of Amgen. He has 1,800,000. Shares.
Also the Future Drug or Protein they have MANF is being tested
for Parkinson's, as well as Alzheimer's treatments long term.
MANF has been found in lab tests to reverse the condition of cell stress and regenerate or revitialize the cells. So it could be used in a treatment for Diabetes, and the neuro diseases mentioned above, as well has having a diagnostic coming on line this year Lympro for Alzeheimers.
Thank you for your time, I"m just a shareholder of AMBS and hope others see what I see in this one.
I might sell 3/4 of my holdings when its .50 cents, but will hold on to some shares for the long haul.
Can you say KABOOM profits were taken huge not me
I'm LONG
KABOOM - The sound of Profit takers. AFter taxes they will not
be able to recover their position. This must be the Stock Roach,
roaches doing this selling.
Anyway, I'm not selling a single share only buying.
Hopefully you Roaches hold this down One more Day for me.
This CEO needs to go. S1? what a joke.
We need a Joint Venture, Update today.
I buy every couple of weeks sometimes a lot sometimes a little but my position is sizable and I"m confident it will perform,
I just don't like all the back room financing going on,
I want to see some Share Holder Value here.
Did they really get 30,000,000
Can you prove it?